ASCO 2025 Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025 Donwload Press release (PDF)
Category: Tools-Home-ImagesUne
Presentation
Transgene in a nutshell Download(PDF) Corporate Presentation Download(PDF) Universal Registration Document Download(PDF)